Sign up to save your podcasts
Or
Share Accelerating Evidence-Based Care in LA SCCHN
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Accelerating Evidence-Based Care in LA SCCHN
CME credits: 0.25
Valid until: 22-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/accelerating-evidence-based-care-in-la-scchn/16196/
The emergence of early clinical endpoints compared to the current gold standard of overall survival may change the landscape of how clinical trials are designed as well as how patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) are managed. At the forefront of this change are unique small molecule agents that help to overcome the inhibitory influence of tumors on the apoptotic pathway. Join Drs. Ezra Cohen and Susan Yom as they focus on why utilizing early endpoints in clinical trials, and eventually the clinic, may provide therapeutic advantages compared to our current gold standard of overall survival.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 22-12-2024
Claim your CME credit at https://reachmd.com/programs/cme/accelerating-evidence-based-care-in-la-scchn/16196/
The emergence of early clinical endpoints compared to the current gold standard of overall survival may change the landscape of how clinical trials are designed as well as how patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) are managed. At the forefront of this change are unique small molecule agents that help to overcome the inhibitory influence of tumors on the apoptotic pathway. Join Drs. Ezra Cohen and Susan Yom as they focus on why utilizing early endpoints in clinical trials, and eventually the clinic, may provide therapeutic advantages compared to our current gold standard of overall survival.
=